Vicarious Surgical (RBOT) Capital Leases (2022 - 2023)
Vicarious Surgical's (RBOT) quarterly Capital Leases came in at $14.3 million in Q2 2023, down 6.32% year-on-year from $15.3 million in Q2 2022, and down 1.8% on a QoQ basis from $14.6 million in Q1 2023.
Vicarious Surgical (RBOT) Capital Leases (2022 - 2023) Analysis & Trends
Vicarious Surgical (RBOT) has 2 years of Capital Leases data on file, last reported at $14.3 million in Q2 2023.
- On a quarterly basis, Capital Leases fell 6.32% year-over-year to $14.3 million in Q2 2023; TTM through Jun 2023 was $14.3 million, a 6.32% decrease from a year earlier, with the FY2022 full-year figure at $14.8 million, changed N/A from the prior year.
- Capital Leases for Q2 2023 stood at $14.3 million, down from $14.6 million in the prior quarter.
- Over the last five years, Capital Leases for RBOT reached as high as $15.5 million in Q1 2022 and fell as low as $14.3 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Vicarious Surgical | 654,984.55 | -9.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 14.33 Mn |
| Mar 31, 2023 | 14.59 Mn |
| Dec 31, 2022 | 14.83 Mn |
| Sep 30, 2022 | 15.07 Mn |
| Jun 30, 2022 | 15.30 Mn |
| Mar 31, 2022 | 15.52 Mn |